Author Affiliation: Department of Nutrition, Harvard School of Public Health, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
In the unstable clinical state after an acute coronary disease event,
patients experience a high rate of serious complications including death,
myocardial infarction (MI), and progressively recurring unstable angina requiring
intervention.1 The incidence rate sharply declines
after 1 month, and then gradually diminishes so that after about 6 months,
the incidence of coronary death and MI is fairly constant for the next several
years, reflecting a stabilization of the clinical coronary disease. Many successful
clinical strategies—including antithrombotic therapy, β-adrenergic
blockade, thrombolysis, and angiotensin-converting enzyme inhibition—have
been directed toward reducing the high early event rate after onset of acute
coronary syndrome.1 Nonetheless, the incidence
of serious complications remains high.
Sacks FM. Lipid-Lowering Therapy in Acute Coronary Syndromes. JAMA. 2001;285(13):1758-1760. doi:10.1001/jama.285.13.1758